Abstract

Alzheimer's disease (AD) is associated with non-cognitive symptoms such as changes in feeding behaviour that are often characterised by an increase in appetite. Increased food intake is observed in several mouse models of AD including the triple transgenic (3×TgAD) mouse, but the mechanisms underlying this hyperphagia are unknown. We therefore examined feeding behaviour in 3×TgAD mice and tested their sensitivity to exogenous and endogenous satiety factors by assessing food intake and activation of key brain regions. In the behavioural satiety sequence (BSS), 3×TgAD mice consumed more food after a fast compared to Non-Tg controls. Feeding and drinking behaviours were increased and rest decreased in 3×TgAD mice, but the overall sequence of behaviours in the BSS was maintained. Exogenous administration of the satiety factor cholecystokinin (CCK; 8–30 µg/kg, i.p.) dose-dependently reduced food intake in Non-Tg controls and increased inactive behaviour, but had no effect on food intake or behaviour in 3×TgAD mice. CCK (15 µg/kg, i.p.) increased c-Fos protein expression in the supraoptic nucleus of the hypothalamus, and the nucleus tractus solitarius (NTS) and area postrema of the brainstem to the same extent in Non-Tg and 3×TgAD mice, but less c-Fos positive cells were detected in the paraventricular hypothalamic nucleus of CCK-treated 3×TgAD compared to Non-Tg mice. In response to a fast or a period of re-feeding, there was no difference in the number of c-Fos-positive cells detected in the arcuate nucleus of the hypothalamus, NTS and area postrema of 3×TgAD compared to Non-Tg mice. The degree of c-Fos expression in the NTS was positively correlated to food intake in Non-Tg mice, however, this relationship was absent in 3×TgAD mice. These data demonstrate that 3×TgAD mice show increased feeding behaviour and insensitivity to satiation, which is possibly due to defective gut-brain signalling in response to endogenous satiety factors released by food ingestion.

Highlights

  • Alzheimer’s disease (AD) is a chronic progressive neurodegenerative disorder that is characterised by the accumulation of extracellular beta amyloid (Ab) plaques and neurofibrillary tangles composed of hyperphosphorylated tau [1]

  • Body weight was significantly greater in 36TgAD mice (3-month-old: Non-Tg, 21.960.5 g versus 36TgAD, 28.260.5 g, P,0.001; 6-month-old: Non-Tg, 28.760.5 g versus 36TgAD, 33.960.9 g, P,0.001, n = 6–9), when food intake was expressed as g/kg body weight there was still a significant increase in food consumed in 6month-old 36TgAD mice (3-month-old: Non-Tg, 39.662.5 g/kg versus 36TgAD, 44.862.9 g/kg, P.0.05; 6-month-old: Non-Tg, 15.763.5 g/kg versus 36TgAD, 33.762.7 g, P,0.01)

  • AD is associated with several non-cognitive changes in behaviour such as weight loss and alterations in eating patterns

Read more

Summary

Introduction

Alzheimer’s disease (AD) is a chronic progressive neurodegenerative disorder that is characterised by the accumulation of extracellular beta amyloid (Ab) plaques and neurofibrillary tangles composed of hyperphosphorylated tau [1]. Patients with AD suffer from several non-cognitive behavioural symptoms, including depression, anxiety, agitation, hyperactivity, disturbed circadian rhythms, alterations in eating habits and changes in energy balance such as weight loss [2,3,4,5,6,7]. Non-cognitive behavioural changes in AD can lead to a poorer quality of life and, in some cases, such as severe weight loss, can be life-threatening [8,9,10]. In spite of their serious consequences, the majority of non-cognitive changes in AD are not commonly studied and as such remain poorly understood. Understanding when and how these non-cognitive symptoms of AD occur could lead to a better quality of life for AD patients

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call